Stimulation of Sigma-1 Receptor Ameliorates Depressive-like Behaviors in CaMKIV Null Mice

Mol Neurobiol. 2015 Dec;52(3):1210-1222. doi: 10.1007/s12035-014-8923-2. Epub 2014 Oct 15.

Abstract

Sigma-1 receptor (Sig-1R) is a molecular chaperone regulating calcium efflux from the neuronal endoplasmic reticulum to the mitochondria. Calcium/calmodulin-dependent protein kinase IV (CaMKIV) null mice exhibit depressive-like behaviors and impaired neurogenesis as assessed by bromodeoxyuridine (BrdU) incorporation into newborn cells of the hippocampal dentate gyrus (DG). Here, we demonstrate that chronic stimulation of Sig-1R by treatment with the agonist SA4503 or the SSRI fluvoxamine for 14 days improves depressive-like behaviors in CaMKIV null mice. By contrast, treatment with paroxetine, which lacks affinity for Sig-1R, did not alter these behaviors. Reduced numbers of BrdU-positive cells and decreased brain-derived neurotrophic factor (BDNF) mRNA expression and protein kinase B (Akt; Ser-473) phosphorylation seen in the DG of CaMKIV null mice were significantly rescued by chronic Sig-1R stimulation. Interestingly, reduced ATP production observed in the DG of CaMKIV null mice was improved by chronic Sig-1R stimulation. Such stimulation also improved hippocampal long-term potentiation (LTP) induction and maintenance, which are impaired in the DG of CaMKIV null mice. LTP rescue was closely associated with both increases in calcium/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation and GluA1 (Ser-831) phosphorylation. Taken together, Sig-1R stimulation by SA4503 or fluvoxamine treatment increased hippocampal neurogenesis, which is closely associated with amelioration of depressive-like behaviors in CaMKIV null mice.

Keywords: CaMKIV null mice; Depressive-like behaviors; Hippocampal neurogenesis; Sigma-1R.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / biosynthesis
  • Animals
  • Antidepressive Agents / pharmacology*
  • Brain-Derived Neurotrophic Factor / biosynthesis
  • Brain-Derived Neurotrophic Factor / genetics
  • CA3 Region, Hippocampal / drug effects
  • CA3 Region, Hippocampal / metabolism
  • Calbindins / metabolism
  • Calcium Signaling / drug effects
  • Calcium-Calmodulin-Dependent Protein Kinase Type 4 / deficiency*
  • Dentate Gyrus / drug effects
  • Dentate Gyrus / metabolism
  • Depression / drug therapy*
  • Depression / genetics
  • Depression / metabolism
  • Fluvoxamine / pharmacology
  • Gene Expression Regulation / drug effects
  • Immobilization
  • Long-Term Potentiation / drug effects
  • Male
  • Maze Learning / drug effects
  • Mice
  • Mice, Knockout
  • Nerve Tissue Proteins / biosynthesis
  • Nerve Tissue Proteins / genetics
  • Neurogenesis / drug effects
  • Paroxetine / pharmacology
  • Phosphorylation / drug effects
  • Piperazines / pharmacology
  • Protein Processing, Post-Translational / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, N-Methyl-D-Aspartate / physiology
  • Receptors, sigma / agonists*
  • Receptors, sigma / biosynthesis
  • Receptors, sigma / genetics
  • Sigma-1 Receptor

Substances

  • Antidepressive Agents
  • Brain-Derived Neurotrophic Factor
  • Calbindins
  • Nerve Tissue Proteins
  • Piperazines
  • Receptors, N-Methyl-D-Aspartate
  • Receptors, sigma
  • Paroxetine
  • Adenosine Triphosphate
  • SA 4503
  • Akt1 protein, mouse
  • Proto-Oncogene Proteins c-akt
  • Calcium-Calmodulin-Dependent Protein Kinase Type 4
  • Camk4 protein, mouse
  • Fluvoxamine